MicroRNA binding-site polymorphisms as potential biomarkers of cancer risk

Molecular Diagnosis and Therapy

Volumn 14, Issue 6, 2010, Pages 335-342

  Blitzblau, Rachel C ^a   Weidhaas, Joanne B ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Cancer; Diagnostics; Genetic polymorphism; MicroRNAs, general

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CD68 ANTIGEN; INTERLEUKIN 1ALPHA; K RAS PROTEIN; MICRORNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; XRCC1 PROTEIN;

BINDING SITE; CANCER RISK; GENE CONTROL; GENETIC ASSOCIATION; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

BINDING SITES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICRORNAS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 79551585878     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.2165/11587600-000000000-00000     Document Type: Review

References (33)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004 Jan 23; 116 (2): 281-97
2. Brennecke J, Stark A, Russell RB, et al. Principles of microRNA-target recognition. PLoS Biol 2005 Mar; 3 (3): e85
3. Hutvagner G, Zamore PD. AmicroRNA in a multiple-turnover RNAi enzyme complex. Science 2002 Sep 20; 297 (5589): 2056-60
4. Chen K, Rajewsky N. Deep conservation of microRNA-target relationships and 30 UTR motifs in vertebrates, flies, and nematodes. Cold Spring Harb Symp Quant Biol 2006; 71: 149-56
5. Chen K, Rajewsky N. Natural selection on human microRNA binding sites inferred from SNP data. Nat Genet 2006 Dec; 38 (12): 1452-6
6. Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of mammalian microRNA targets. Cell 2003 Dec 26; 115 (7): 787-98
7. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006 Apr; 6 (4): 259-69
8. Spizzo R, Nicoloso MS, Croce CM, et al. SnapShot: microRNAs in cancer. Cell 2009 May 1; 137 (3): 586-e1
9. Grady WM, Tewari M. The next thing in prognostic molecular markers: microRNA signatures of cancer. Gut 2010 Jun; 59 (6): 706-8
10. Yu Z, Li Z, Jolicoeur N, et al. Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res 2007; 35 (13): 4535-41
11. Landi D, Gemignani F, Barale R, et al. A catalog of polymorphisms falling in microRNA-binding regions of cancer genes.DNACellBiol 2008 Jan; 27 (1): 35-43
12. Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 2007 May; 21 (5): 1132-47
13. Lapidus RG, Nass SJ, Davidson NE. The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 1998 Jan; 3 (1): 85-94
14. LandiD,Gemignani F,Naccarati A, et al. Polymorphisms within micro-RNAbinding sites and risk of sporadic colorectal cancer. Carcinogenesis 2008Mar; 29 (3): 579-84
15. Chin LJ, Ratner E, Leng S, et al. A SNP in a let-7 microRNA complementary site in the KRAS 30 untranslated region increases non-small cell lung cancer risk. Cancer Res 2008 Oct 15; 68 (20): 8535-40
16. Ratner E, Lu L, Boeke M, et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res 2010 Aug 15; 70 (16): 6509-15
17. Saetrom P, Biesinger J, Li SM, et al. A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res 2009 Sep 15; 69 (18): 7459-65
18. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007 Jul; 39 (7): 870-4
19. Song F, Zheng H, Liu B, et al. An miR-502-binding site single-nucleotide polymorphism in the 30-untranslated region of the SET8 gene is associated with early age of breast cancer onset. Clin Cancer Res 2009 Oct 1; 15 (19): 6292-300
20. Gao Y, He Y, Ding J, et al. An insertion/deletion polymorphism at miRNA- 122-binding site in the interleukin-1alpha 30 untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis 2009 Dec; 30 (12): 2064-9
21. Chen S, He Y, Ding J, et al. An insertion/deletion polymorphism in the untranslated region of beta-transducin repeat-containing protein (betaTrCP) is associated with susceptibility for hepatocellular carcinoma in Chinese. Biochem Biophys Res Commun 2010 Jan 1; 391 (1): 552-6
22. ZhouX, Chen X, Hu L, et al. Polymorphisms involved in themiR-218-LAMB3 pathway and susceptibility of cervical cancer, a case-control study in Chinese women. Gynecol Oncol 2010 May; 117 (2): 287-90
23. Martinez I, Gardiner AS, Board KF, et al. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 2008 Apr 17; 27 (18): 2575-82
24. Nicoloso MS, Sun H, Spizzo R, et al. Single-nucleotide polymorphisms inside microRNAtarget sites influence tumor susceptibility. Cancer Res 2010 Apr 1; 70 (7): 2789-98
25. Johnson N, Fletcher O, Palles C, et al. Counting potentially functional variants in BRCA1, BRCA2 andATMpredicts breast cancer susceptibility. Hum Mol Genet 2007 May 1; 16 (9): 1051-7
26. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007 Jun 28; 447 (7148): 1087-93
27. Kontorovich T, LevyA,KorostishevskyM, et al. Single nucleotide polymorphisms inmiRNA binding sites and miRNAgenes as breast/ovariancancer riskmodifiers in Jewish high-risk women. Int J Cancer 2010 Aug 1; 127 (3): 589-97
28. Brendle A, Lei H, Brandt A, et al. Polymorphisms in predicted microRNAbinding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. Carcinogenesis 2008 Jul; 29 (7): 1394-9
29. Christensen BC, Moyer BJ, Avissar M, et al. A let-7 microRNA-binding site polymorphism in the KRAS 30 UTR is associated with reduced survival in oral cancers. Carcinogenesis 2009 Jun; 30 (6): 1003-7
30. Graziano F, Canestrari E, Loupakis F, et al. Genetic modulation of the Let-7 microRNA binding to KRAS 30-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J 2010 Oct; 10 (5): 458-64
31. Zhang W, Winder T, Ning Y, et al. A let-7 microRNA-binding site polymorphism in 30-untranslated region of KRAS gene predicts response in wildtype KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol 2011 Jan; 22 (1): 104-9
32. Nelson HH, Christensen BC, Plaza SL, et al. KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. Lung Cancer 2010 Jul; 69 (1): 51-3
33. Sethupathy P, Collins FS. MicroRNA target site polymorphisms and human disease. Trends Genet 2008 Oct; 24 (10): 489-97